miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20324-20337

  Gao, Yu ^a   Ma, Xin ^a   Yao, Yuanxin ^a   Li, Hongzhao ^a   Fan, Yang ^a   Zhang, Yu ^a   Zhao, Chaofei ^a   Wang, Lei ^a   Ma, Minghui ^a   Lei, Zhengwei ^a   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Clear cell renal cell carcinoma; E2F2; miR 155; Proliferation and invasion

Indexed keywords

MICRORNA 155; TRANSCRIPTION FACTOR E2F2; E2F2 PROTEIN, HUMAN; MICRORNA; MIRN155 MICRORNA, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; RENAL CELL CARCINOMA; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CELL MOVEMENT; CELL PROLIFERATION; E2F2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964770437     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7951     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA. 2013; 63:11-30.
2. Capitanio U, Montorsi F. Renal cancer. Lancet. 2015; doi: 10.1016/S0140-6736(15)00046-X.
3. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC, European Association of Urology Guideline G. EAU guidelines on renal cell carcinoma: the 2010 update. European urology. 2010; 58:398-406.
4. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, Spahn M, Mareel M. Radiotherapy for renal-cell carcinoma. The Lancet Oncology. 2014; 15:e170-177. doi: 10.18632/oncotarget.2374.
5. Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer. 2015; 51:2580-6.
6. Lamuraglia M, Raslan S, Elaidi R, Oudard S, Escudier B, Slimane K, Penna RR, Wagner M, Lucidarme O. mTORinhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response. Eur Radiol. 2016; 26:278-85.
7. Oudard S, Vano Y. The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma. Current opinion in urology. 2015; 25:402-410. doi: 10.18632/oncotarget.4959.
8. Zanardi E, Verzoni E, Grassi P, Necchi A, Giannatempo P, Raggi D, De Braud F, Procopio G. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Therapeutic advances in urology. 2015; 7:152-161.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, function. Cell. 2004; 116:281-297.
10. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science. 2003; 301:336-338.
11. Song C, Xu Z, Jin Y, Zhu M, Wang K, Wang N. The network of microRNAs, transcription factors, target genes and host genes in human renal cell carcinoma. Oncology letters. 2015; 9:498-506.
12. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clinical cancer research. 2014; 20:2617-2630.
13. Ge YZ, Xin H, Lu TZ, Xu Z, Yu P, Zhao YC, Li MH, Zhao Y, Zhong B, Xu X, Zhou LH, Wu R, Xu LW, et al. MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma. Scientific reports. 2015; 5:10328.
14. Christinat Y, Krek W. Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer. Oncotarget. 2015; 6:10521-10531. doi: 10.18632/oncotarget.3294.
15. Xiang W, He J, Huang C, Chen L, Tao D, Wu X, Wang M, Luo G, Xiao X, Zeng F, Jiang G. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget. 2015; 6:4066-4079. doi: 10.18632/oncotarget.2926.
16. Su Z, Ni L, Yu W, Yu Z, Chen D, Zhang E, Li Y, Wang Y, Li X, Yang S, Gui Y, Lai Y, Ye J. MicroRNA-451a is associated with cell proliferation, migration and apoptosis in renal cell carcinoma. Molecular medicine reports. 2015; 11:2248-2254.
17. Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q, Gao Y, Li X, Gu L, Xiu S, Bao X, Duan J, Zhang X. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urologic oncology. 2015; 33:169 e161-111.
18. Li T, Yang J, Lv X, Liu K, Gao C, Xing Y, Xi T. miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnology letters. 2014; 36:1743-1752.
19. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer research. 2010; 70:3119-3127.
20. Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of pathology. 2015; 236:445-456.
21. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochimica et biophysica acta. 2002; 1602:131-150.
22. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes & development. 2001; 15:267-285.
23. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005; 24:2810-2826.
24. McClellan KA, Ruzhynsky VA, Douda DN, Vanderluit JL, Ferguson KL, Chen D, Bremner R, Park DS, Leone G, Slack RS. Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycle-independent functions. Molecular and cellular biology. 2007; 27:4825-4843.
25. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. The Journal of pathology. 2008; 216:418-427.
26. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. Journal of cellular and molecular medicine. 2009; 13:3918-3928.
27. Yi Z, Fu Y, Zhao S, Zhang X, Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. Journal of cancer research and clinical oncology. 2010; 136:855-862.
28. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS. Identification of a microRNA panel for clear-cell kidney cancer. Urology. 2010; 75:835-841.
29. Liu F, Kong X, Lv L, Gao J. TGF-beta1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer letters. 2015; 359:288-298.
30. Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jonson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell cycle. 2013; 12:1939-1947.
31. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013; 122:243-252.
32. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology. 2012; 56:1631-1640.
33. Jiang YX, Du ZM, Jiao L, Shao Q, Fu S, Shao JY, Zhu XF, Ernberg I, Li YH. Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. International journal of clinical and experimental medicine. 2015; 8:8472-8484.
34. Huffaker TB, O'Connell RM. miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof. Immunity. 2015; 43:3-4.
35. Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Molecular medicine reports. 2012; 5:949-954.
36. Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ, Duan Z. MicroRNA-155 expression is independently predictive of outcome in chordoma. Oncotarget. 2015; 6:9125-9139. doi: 10.18632/oncotarget.3273.
37. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014; 33:679-689.
38. Lv ZC, Fan YS, Chen HB, Zhao DW. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour biology. 2015; 36:1619-1625.
39. Qu YL, Wang HF, Sun ZQ, Tang Y, Han XN, Yu XB, Liu K. Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma. International journal of clinical and experimental pathology. 2015; 8:6988-6994.
40. Peng Y, Dong W, Lin TX, Zhong GZ, Liao B, Wang B, Gu P, Huang L, Xie Y, Lu FD, Chen X, Xie WB, He W, et al. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget. 2015; 6:16043-16058. doi: 10.18632/oncotarget.3755.
41. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J, Orringer D, Trikha P, Saavedra HI, Leone G. E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop. Molecular and cellular biology. 2007; 27:65-78.
42. Infante A, Laresgoiti U, Fernandez-Rueda J, Fullaondo A, Galan J, Diaz-Uriarte R, Malumbres M, Field SJ, Zubiaga AM. E2F2 represses cell cycle regulators to maintain quiescence. Cell cycle. 2008; 7:3915-3927.
43. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Annals of the New York Academy of Sciences. 2006; 1091:270-281.
44. Wenzel PL, Chong JL, Saenz-Robles MT, Ferrey A, Hagan JP, Gomez YM, Rajmohan R, Sharma N, Chen HZ, Pipas JM, Robinson ML, Leone G. Cell proliferation in the absence of E2F1-3. Developmental biology. 2011; 351:35-45.
45. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, et al. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:15400-15405.
46. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
47. Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W, Zhang P, Song E, Huang Q, Ai Q, Li H, Wang B, Zheng T, et al. Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PloS one. 2013; 8:e73436.
48. Ma X, Gu L, Li H, Gao Y, Li X, Shen D, Gong H, Li S, Niu S, Zhang Y, Fan Y, Huang Q, Lyu X, et al. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma. Journal of translational medicine. 2015; 13:56.